ClinicalTrials.gg
RecruitingNCT07620184SNaPsUpdated Jun 4, 2026

Swedish National Parotidectomy Study (SNaPs): Drainless Versus Standard Surgery

An interventional study of Active wound drainage (Standard of Care) and Omission of active wound drain in Parotid Neoplasms, Post-operative Complications and Seroma as Procedural Complication, sponsored by Uppsala University Hospital. Recruiting at 3 sites in Sweden. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Uppsala University Hospital · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study The purpose of this study is to find out if it is safe to perform surgery on the parotid gland (the large salivary gland in front of the ear) without using a wound drain. A wound drain is a small plastic tube used to remove excess fluid from the surgical site after the operation. Currently, using a drain is the standard practice in Sweden, which often means patients must stay in hospital overnight. Researchers want to see if skipping the drain is just as safe and if it could allow more patients to return home on the same day as their surgery.

What happens during the study

Participants in this study will be randomly assigned to one of two groups during their surgery:

Group 1: Will receive the standard treatment with a wound drain.

Group 2: Will have the surgery performed without a wound drain.

Apart from the use of a drain, all participants will receive the same surgical care. After the operation, researchers will monitor the healing process. Participants will be asked to fill out questionnaires about their health and any symptoms at one week and six months after their surgery.

The goal of the study The main goal is to compare the safety of the two methods. Researchers will look at whether there is any difference in the number of complications, such as fluid build-up (seroma), bleeding, or infections, between those who had a drain and those who did not. The study also aims to evaluate if avoiding a drain improves the patient's quality of life and if it is a more cost-effective approach for the healthcare system.

02

Conditions studied

  • Parotid Neoplasms
  • Post-operative Complications
  • Seroma as Procedural Complication

Keywords

  • Parotidectomy
  • Surgical drainage
  • Wound drains
  • Postoperative complications
  • Seroma
  • Hematoma
  • Randomised controlled trial
  • Non-inferiority
  • Salivary gland surgery
  • Quality of life
03

In context

Parotid Neoplasms

27 studies on the registry are indexed under Parotid Neoplasms; 7 are open to participants now.

This study's planned enrollment of 600 is above the median of 55 across 18 interventional studies indexed under Parotid Neoplasms.

Browse Parotid Neoplasms studies →

Lead sponsor

Uppsala University Hospital is the lead sponsor of 73 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients scheduled to undergo partial or superficial parotidectomy without concurrent soft tissue surgery, in cases where a wound drain is traditionally used (extirpation of single adjacent lymph nodes is acceptable).
  • class 1-3.
  • Aged 18 years or older.
  • The patient understands the participant information and is able to make an informed choice.

Exclusion criteria

Exclusion Criteria:

  • Previous parotid surgery on the same side
  • Tumour with parapharyngeal extension.
  • Ongoing or planned perioperative treatment with tranexamic acid.
  • Ongoing treatment with dual antiplatelet therapy (single agent therapy, such as Aspirin or Clopidogrel, is not an exclusion criterion).
  • Ongoing treatment with anticoagulants (NOAC, Warfarin) at the time of surgery. NOAC must be discontinued at least 24 hours before surgery.
  • Ongoing treatment with low molecular weight heparin in doses higher than: Fragmin 5000 IU/day, Clexane 40 mg/day, or Innohep 4500 IU/day.Ongoing treatment for .Known coagulation disorder.
  • count \<150 x 10⁹
  • PK- >1.2.
  • \<120 g/L.
  • APTT >42s.
  • Preoperative impaired facial nerve function on the affected side (Sunnybrook Facial Grading System score \<90).
  • Supplementary postoperative treatment such as radiotherapy or extended surgery.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Drainless Group (Intervention)

    Participants in this group will undergo partial or superficial parotidectomy without the placement of a postoperative active wound drain. The surgical site is closed according to the standard technique, but the suction drain is omitted.

    Procedure: Omission of active wound drain

  • Active comparator
    Standard Drain Group (Control)

    Participants in this group will undergo partial or superficial parotidectomy with the placement of a postoperative active wound drain, according to current standard clinical routine in Sweden.

    Procedure: Active wound drainage (Standard of Care)

Interventions

  • ProcedureActive wound drainage (Standard of Care)

    An active suction drain is placed in the surgical bed before wound closure, which is the current established clinical practice for parotidectomy in Sweden.

  • ProcedureOmission of active wound drain

    The surgical procedure is performed without the insertion of an active suction drain. All other aspects of the surgical care and postoperative monitoring follow standard protocols.

06

What researchers measure

Primary outcomes

  1. Cumulative incidence of early postoperative complications requiring intervention

    The primary outcome is the number of participants experiencing at least one early complication, defined as a salivary fistula, haematoma, seroma/sialocele, or surgical site infection that requires invasive or medical treatment (e.g., aspiration, re-operation, or antibiotics).

    Time frame: From the day of surgery up to 7 weeks postoperatively.

Secondary outcomes

  1. Requirement for inpatient hospital care after the day of surgery.

    Evaluation of the number of participants requiring unplanned hospital admission or prolonged stay related to the surgical procedure.

    Time frame: From the first postoperative day up to 6 months

  2. Postoperative facial nerve function.

    Assessment of facial nerve function using the Sunnybrook Facial Grading System (SFGS). The SFGS is a clinical evaluation scale that ranges from 0 to 100. A score of 0 indicates complete facial paralysis, while a score of 100 represents normal facial function. Higher scores indicate a better outcome (better facial nerve function).

    Time frame: Baseline (preoperative), at discharge, at 7 weeks, and at 6 months

  3. Incidence of Frey's syndrome

    Subjective and objective assessment of gustatory sweating (Frey's syndrome).

    Time frame: 6 months postoperatively.

  4. Health-related quality of life (EQ-5D-5L)

    Evaluated using the EQ-5D-5L descriptive system, which comprises 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension is scored from 1 (no problems) to 5 (extreme problems). The digits are combined into a 5-digit health state profile, which is then converted into a single index value. Index values range from less than 0 (where 0 is a state equivalent to death and negative values are states worse than death) to 1.0 (perfect health). Higher scores indicate a better quality of life outcome.

    Time frame: 7 weeks, and 6 months postoperatively

  5. Postoperative length of stay

    Total number of days spent in hospital following the surgical procedure.

    Time frame: Through initial hospital discharge, an average of 1.5 days, assessed up to 7 weeks.

  6. Symptom-specific outcomes (SwPOI-8)

    Measured using the Swedish Parotidectomy Outcome Inventory 8 (SwPOI-8), a disease-specific instrument assessing subjective symptoms after parotid surgery (e.g., pain, sensory disturbances, scarring, facial palsy, sweating, dry mouth). Each of the 8 items is scored on a Likert scale from 0 to 3, with a total score ranging from 0 to 24. Higher scores indicate a greater symptom burden and a worse outcome.

    Time frame: 7 weeks and 6 months postoperatively

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared publicly due to current Swedish legislation and the European General Data Protection Regulation (GDPR), which protect the privacy of study participants. Sharing of pseudonymised individual-level data would require specific legal review and institutional agreements to ensure continued data protection

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Dec 2030, 55 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
Jun 2, 2026
StartActual
May 6, 2026
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2032
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07620184
Lead sponsor
Uppsala University Hospital
Collaborators
Uppsala University, Västra Götalandsregionen, Göteborg University
Responsible party
Karl Sandström (Clinical associated professor, Uppsala University Hospital) — Principal investigator
First posted
Jun 2, 2026
Start date
May 6, 2026
Primary completion
Dec 2030 (estimated)
Completion
Dec 2032 (estimated)
Last update
Jun 4, 2026

Study contacts

Karl Sandström, MD, PhD
Contact
karl.sandstrom@akademiska.se
+46 76 113 29 52

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion